H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Timber Pharmaceuticals (NYSE: TMBR) to $1.00 (from $1.50) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE